Why We Believe Biopharma Is Set For A Comeback [November 30, 2023 HedgeD, With A Capital “D” Webinar Series]

HedgeD

Contenido proporcionado por Nick Taylor, Morgan Creek Capital Management, and LLC. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Nick Taylor, Morgan Creek Capital Management, and LLC o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

9M ago 41:34

MP3•Episodio en casa

In this episode of HedgeD, we replay the November 30th, 2023 HedgeD, With A Capital “D” webinar where Mark Yusko and Cory Lester talked about why they are so constructive on the outlook for Biopharma stocks. The fundamental disconnect between where Biopharma stocks are trading and the innovation and advancements in treatments reached an extreme level in 2023, in their opinion. They believe it is only a matter of time before investor attention returns to the sector focused on the science rather than the macro environment. We hope you enjoy the conversation.

You can @ us on Twitter @HedgeD_Podcast or email us directly at HedgeD@morgancreekcap.com

Visit us on the web at https://www.morgancreekcap.com/opportunistic-equity/

Join our almost monthly HedgeD, With A Capital “D” webinar series by emailing HedgeD@morgancreekcap.com

And subscribe to our YouTube channel by visiting https://www.youtube.com/channel/UC8RssLKui3GNrxlOtYk6jRQ

44 episodios

#Trading #Business #Nick Taylor #LLC #Morgan Creek Capital Management #Finance #Investing #Hedgefund